secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evoke Pharma Inc (—)
CIK:        0001403708
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059570
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evoke Pharma Q1 net product sales up 114% to $1.7M; reiterates $14M 2024 guidance
--------------------------------------------------------------------------------

- Net product sales of $1.7M vs $0.8M in Q1 2023; net loss of $1.6M ($0.17/share) improved from $2.2M ($0.67/share).
- Prescriber count grew 70% QoQ; medication fills increased 10% in Q1 2024 despite February cyberattack on claims processor.
- Raised $8.8M gross from public offering and warrant exercises; cash $9.7M expected to fund ops into Q1 2025.
- Reaffirmed full-year 2024 net revenue guidance of approximately $14M.
- Strengthened distribution partnership with ASPN Pharmacies and plans to present nasal metoclopramide data at DDW 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1403708/000095017024059570/0000950170-24-059570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1403708/000095017024059570/evok-20240514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer